secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001628280-23-020692
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo shareholders approve doubling authorized common stock to 640M and 10M share increase to equity plan
--------------------------------------------------------------------------------

- Authorized common stock increased from 320M to 640M shares; filings made June 2, 2023.
- 2018 Equity Incentive Plan amended to add 10M shares; max incentive stock options raised to 73.2M shares.
- Amendment adopted to limit officer monetary liability for breach of fiduciary duty under Delaware law.
- All nine director nominees elected; advisory Say-on-Pay approved with 87.4% of votes cast For.
- Advisory vote on executive compensation frequency set to every year going forward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/0001628280-23-020692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230601.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-020692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer